These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 37983810)

  • 1. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Lazarus JV; Newsome PN; Francque SM; Kanwal F; Terrault NA; Rinella ME
    Hepatology; 2024 Mar; 79(3):E93-E94. PubMed ID: 37983810
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hoofnagle JH; Doo E
    Hepatology; 2024 Mar; 79(3):E91-E92. PubMed ID: 37983836
    [No Abstract]   [Full Text] [Related]  

  • 3. Reclassification of nonalcoholic fatty liver disease: a multi-society Delphi consensus statement.
    Bajo FR; Shipman KE
    Clin Exp Dermatol; 2023 Nov; 48(12):1418-1421. PubMed ID: 37616524
    [No Abstract]   [Full Text] [Related]  

  • 4. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    J Hepatol; 2023 Dec; 79(6):1542-1556. PubMed ID: 37364790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Narro GEC; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    Ann Hepatol; 2024; 29(1):101133. PubMed ID: 37364816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    Hepatology; 2023 Dec; 78(6):1966-1986. PubMed ID: 37363821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
    Eslam M; Sanyal AJ; George J;
    Gastroenterology; 2020 May; 158(7):1999-2014.e1. PubMed ID: 32044314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    Xu X; Nan Y
    J Hepatol; 2022 Feb; 76(2):484-485. PubMed ID: 34774637
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.
    Arab JP; Candia R; Zapata R; Muñoz C; Arancibia JP; Poniachik J; Soza A; Fuster F; Brahm J; Sanhueza E; Contreras J; Cuellar MC; Arrese M; Riquelme A
    World J Gastroenterol; 2014 Sep; 20(34):12182-201. PubMed ID: 25232252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group.
    McPherson S; Armstrong MJ; Cobbold JF; Corless L; Anstee QM; Aspinall RJ; Barclay ST; Brennan PN; Cacciottolo TM; Goldin RD; Hallsworth K; Hebditch V; Jack K; Jarvis H; Johnson J; Li W; Mansour D; McCallum M; Mukhopadhya A; Parker R; Ross V; Rowe IA; Srivastava A; Thiagarajan P; Thompson AI; Tomlinson J; Tsochatzis EA; Yeoman A; Alazawi W
    Lancet Gastroenterol Hepatol; 2022 Aug; 7(8):755-769. PubMed ID: 35490698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
    Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
    J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
    Eslam M; George J
    J Hepatol; 2020 Nov; 73(5):1268-1269. PubMed ID: 32800588
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    Eslam M; George J
    J Hepatol; 2020 Dec; 73(6):1575. PubMed ID: 32933781
    [No Abstract]   [Full Text] [Related]  

  • 14. Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature.
    Yoon EL; Jun DW
    Gut Liver; 2022 May; 16(3):319-320. PubMed ID: 35551103
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent International Consensus-Based Changes in the Diagnostic Criteria and Nomenclature of Nonalcoholic Fatty Liver Disease.
    Mubarak M
    J Coll Physicians Surg Pak; 2024 Jan; 34(1):2-4. PubMed ID: 38185951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAKISTAN SOCIETY OF HEPATOLOGY (PSH) POSITION STATEMENT: RENAMING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) TO STEATOTIC LIVER DISEASE (SLD), ENDORSEMENT OF NEW MULTI-SOCIETY NOMENCLATURE.
    Ali Z; Riaz M; Alam A; Faroqi JI
    J Ayub Med Coll Abbottabad; 2023; 35(4):700-702. PubMed ID: 38406965
    [No Abstract]   [Full Text] [Related]  

  • 17. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement.
    Hagström H; Adams LA; Allen AM; Byrne CD; Chang Y; Duseja A; Grønbæk H; Ismail MH; Jepsen P; Kanwal F; Kramer J; Loomba R; Mark HE; Newsome PN; Rinella ME; Rowe IA; Ryu S; Sanyal A; Schattenberg JM; Serper M; Sheron N; Simon TG; Spearman CW; Tapper EB; Villota-Rivas M; Wild SH; Wong VW; Yilmaz Y; Zelber-Sagi S; Åberg F; Lazarus JV
    Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38315102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
    Maevskaya MV; Kotovskaya YV; Ivashkin VT; Tkacheva ON; Troshina EA; Shestakova MV; Breder VV; Geyvandova NI; Doshchitsin VL; Dudinskaya EN; Ershova EV; Kodzoeva KB; Komshilova KA; Korochanskaya NV; Mayorov AY; Mishina EE; Nadinskaya MY; Nikitin IG; Pogosova NV; Tarzimanova AI; Shamkhalova MS
    Ter Arkh; 2022 Feb; 94(2):216-253. PubMed ID: 36286746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".
    Mak LY; Yuen MF; Seto WK
    J Hepatol; 2020 Dec; 73(6):1573-1574. PubMed ID: 32951910
    [No Abstract]   [Full Text] [Related]  

  • 20. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.
    Shiha G; Alswat K; Al Khatry M; Sharara AI; Örmeci N; Waked I; Benazzouz M; Al-Ali F; Hamed AE; Hamoudi W; Attia D; Derbala M; Sharaf-Eldin M; Al-Busafi SA; Zaky S; Bamakhrama K; Ibrahim N; Ajlouni Y; Sabbah M; Salama M; Anushiravani A; Afredj N; Barakat S; Hashim A; Fouad Y; Soliman R
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):57-64. PubMed ID: 33181119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.